Cooper Companies offers a rare combination of recurring medical-device revenue, durable contact lens share gains, improving margins, and litigation-discounted valuation, creating an asymmetric five-year risk-reward profile.
Cooper Companies Inc is a leading global medical device developer specializing in ophthalmic care and reproductive health platforms.[1] The company operates through two highly specialized business segments: CooperVision, which delivers soft contact lenses and vision correction devices, and CooperSurgical, which provides medical instruments, long-acting reversible contraceptives, and fertility lab consumables.[1, 2] Cooper Companies generates its revenue primarily through a recurring, high-volume consumables model, selling direct-to-clinic and through optical retail channels globally.[3, 4, 5] Geographically, the business is highly diversified, serving customers across the Americas, Europe, the Middle East, Africa (EMEA), and the Asia-Pacific (APAC) regions, with major manufacturing and logistical hubs positioned to support eye care clinics and surgical centers in over 130 countries.[1, 6, 7]
The company’s core products include premium daily disposable silicone hydrogel contact lenses under the MyDay and clariti 1 day brands, frequent replacement lenses within the Biofinity and Avaira families, and the clinically validated MiSight 1 day lens for pediatric myopia management.[5, 8] CooperSurgical’s portfolio is anchored by the PARAGARD non-hormonal copper intrauterine device, specialized in-vitro fertilization (IVF) consumables and embryo culture media, the ZyMot sperm separation device, and the Witness automated laboratory tracking system.[3, 9, 10] The primary customer types consist of independent eye care practitioners, global optical retail chains, obstetricians and gynecologists, and embryologists at fertility clinics.[3, 5] The most important end markets include corrective vision care, pediatric myopia management, long-acting reversible contraception, and clinical fertility genomics.[3, 8, 11] Customers select Cooper Companies over alternatives due to its industry-leading toric and multifocal lens designs, advanced silicone hydrogel materials that optimize corneal oxygenation and daily comfort, and the integrated, end-to-end nature of its IVF laboratory and clinical testing services.[3, 4, 5]
CooperVision’s revenue generation is centered on premium contact lens technologies designed to resolve complex refractive errors. The daily disposable silicone hydrogel portfolio, led by the MyDay and clariti families, represents the primary driver of top-line expansion, offering high oxygen permeability and moisture retention that minimize the risk of corneal hypoxia.[4, 8] In the specialized pediatric space, the MiSight 1 day lens uses a dual-focus optical design to slow the elongation of the child's eye, addressing a major global health epidemic in pediatric myopia.[5, 8]
CooperSurgical’s fertility sub-segment delivers advanced genomic screening and IVF laboratory consumables, such as LifeGlobal global embryo culture media.[3, 9] These clinical media solutions are paired with the ZyMot sperm separation device and the Witness automated tracking system to increase workflow efficiency and procedural safety in laboratories.[3] In the contraception market, CooperSurgical sells PARAGARD, the only non-hormonal intrauterine device approved in the United States to prevent pregnancy for up to 10 years, utilizing copper ions to impair sperm motility without the systemic side effects of hormonal alternatives.[10, 12]
Cooper Companies possesses a deep economic moat structured around high customer switching costs, strong brand equity, regulatory barriers, scale advantages, and intellectual property. In the contact lens market, prescriptions are legally brand-specific, requiring patients to undergo a clinical fitting with an eye care practitioner before they can transition to a competitor.[5, 13] Once fitted with a daily silicone hydrogel lens like MyDay, patients rarely switch, creating a highly recurring subscription-like revenue stream.[3, 5]
The regulatory barriers to entry are substantial; contact lenses and intrauterine devices are classified as high-risk medical devices or combination products by the FDA, requiring years of clinical trials to prove efficacy and safety.[14] Furthermore, the market for soft contact lenses operates as a consolidated global oligopoly, where Cooper occupies a leading position alongside Johnson & Johnson Vision and Alcon.[5, 15] The company's massive high-volume manufacturing facilities and global distribution channels yield a cost and scale advantage that smaller regional players cannot replicate, enabling high gross margins across multiple market cycles.[2, 5]
The global contact lens market exhibits highly durable growth dynamics. The total addressable market was valued at USD 18.88 billion in 2025 and is projected to expand to USD 29.10 billion by 2035, growing at a compound annual growth rate (CAGR) of 4.42% from 2026 to 2035.[4] Alternative market research estimates the global market at USD 9.73 billion in 2025, reaching USD 10.37 billion in 2026 (CAGR 6.6%), and growing to USD 13.36 billion by 2030 at a CAGR of 6.5%.[16] Daily disposables represent the fastest-growing usability segment, holding a 49.05% share of the market in 2025 with an expected CAGR of 4.84% through 2031, supported by higher unit pricing and hygienic benefits that appeal to affluent consumers.[11] Silicone hydrogel materials dominate the material mix, accounting for approximately 55.12% to 65.38% of global volume.[4, 11] The global cosmetic contact lens market, which was valued at USD 1.5 billion in 2025 and is projected to reach USD 2.9 billion by 2035 at a CAGR of 7.1%, represents a highly profitable expansion opportunity where Cooper is the global market leader with a 7.0% market share in 2025.[17]
The global soft contact lens market is characterized by a stable competitive structure.
| Competitor | Estimated Global Share | Key Product Franchises | Strategic Positioning and Dynamics |
|---|---|---|---|
| Johnson & Johnson Vision | ~35% - 40% [15] | Acuvue Oasis, Acuvue 1-Day [5, 18] | Dominant market leader with premium pricing, high consumer advertising, and strong practitioner education programs.[5] |
| Alcon | ~25% [15] | Dailies Total1, Precision1 [5] | Focuses on materials science, high-end daily silicone hydrogel lenses, and surgical cross-selling.[5] |
| CooperVision | ~25% [5, 15] | MyDay, Biofinity, MiSight, clariti [8] | Global leader in toric and multifocal designs, early-mover in pediatric myopia control, and consistent share gainer.[3, 5] |
| Bausch + Lomb | ~5% - 10% [5] | Biotrue ONEday, INFUSE [5] | Positions as a diversified eye-health brand, competing in value segments and selective daily innovations.[5] |
CooperVision continues to gain ground, marking its 18th consecutive year of market share growth in calendar year 2025, with sales expanding 6% compared to the overall market's 5% growth.[3]
In the women's health and intrauterine contraception space, CooperSurgical has historically held a near-monopoly on non-hormonal copper intrauterine devices with PARAGARD.[14] However, the competitive landscape has evolved with the February 2025 FDA approval of Sebela Pharmaceuticals' Miudella (Veracept), the first new non-hormonal copper IUD in 40 years.[12, 19] In February 2026, Organon licensed global marketing rights to Miudella for USD 27.5 million upfront plus up to USD 532 million in milestones.[12] While Miudella features a smaller, more flexible design that reduces the bleeding and pain associated with PARAGARD, its current approval is limited to 3 years compared to PARAGARD’s 10 years, and it is subject to a restrictive REMS training program for clinical providers.[12, 14]
Cooper Companies reported its fiscal second quarter 2026 financial results on June 4, 2026, for the three months ended April 30, 2026.[2, 20] The company reported record net sales of USD 1.082 billion, up 8% reported, or 5% organically, compared to USD 1.00 billion in the second quarter of fiscal year 2025.[2, 20] This exceeded Wall Street's consensus expectations of USD 1.05 billion by 2.7%, representing a USD 32 million beat.[13] Non-GAAP diluted earnings per share reached USD 1.21, up 26% year-over-year from USD 0.96, beating analyst expectations of USD 1.10 by 10.5% (or USD 0.11).[2, 13, 21]
GAAP diluted earnings per share fell to negative USD 0.40, down from positive USD 0.44 in the prior-year period.[2] This GAAP net income reduction was driven by a net pre-tax litigation-related charge of USD 271.6 million recognized within selling, general, and administrative (SG&A) expenses, reflecting a gross accrued liability of USD 324.1 million offset by USD 52.5 million in expected insurance recoveries.[9] This charge was taken to resolve substantially all outstanding product liability claims associated with a December 2023 voluntary recall of specific lots of LifeGlobal embryo culture media at CooperSurgical.[2, 9]
Following the earnings release on June 4, 2026, the stock price reacted favorably, gaining 8.56% to close at USD 67.33 on elevated trading volume, as investors welcomed the resolution of the litigation liability and the strong underlying non-GAAP profitability.[20]
The fiscal second quarter of 2026 demonstrated positive operational performance across both key business segments, despite currency and geographic headwinds.[2]
| Segment / Geography | Q2 2026 Net Sales (Millions USD) | YoY Change (Reported) | YoY Change (Organic) | Key Drivers and Market Dynamics |
|---|---|---|---|---|
| CooperVision (CVI) | USD 723.5 | 8% | 4% | Continued global rollout of premium daily silicone hydrogel portfolio.[2, 3] |
| CVI: Americas | USD 303.2 | 7% | 7% | Solid commercial momentum and private label contract expansions.[3, 6] |
| CVI: EMEA | USD 289.7 | 17% | 6% | Growth offset by an 11% negative foreign exchange impact.[6] |
| CVI: Asia Pacific | USD 130.6 | -6% | -6% | Softness in Japan legacy hydrogels and e-commerce channel normalizations.[6, 8, 22] |
| CooperSurgical (CSI) | USD 358.0 | 8% | 6% | Strong performance in clinical fertility and lab genomics.[2, 3] |
| CSI: Office & Surgical | USD 214.2 | 4% | 4% | Moderate growth, offset by competitive discounting on PARAGARD.[20, 22] |
| CSI: Fertility | USD 143.8 | 13% | 10% | Recovery in IVF consumables, genomic testing, and lab system installations.[3, 20] |
On June 4, 2026, management revised its full-year fiscal 2026 outlook.[2] Total revenue guidance was lowered to a range of USD 4.285 billion to USD 4.321 billion (organic growth of 3.5% to 4.5%).[2] This represents a minor downward adjustment from the early March guidance of USD 4.306 billion to USD 4.346 billion (organic growth of 4.5% to 5.5%), a 0.5% decrease at the midpoint.[13, 21, 23] Within this guidance, CooperVision revenue is projected at USD 2.883 billion to USD 2.908 billion (down from USD 2.906 billion to USD 2.932 billion in March), and CooperSurgical revenue is projected at USD 1.402 billion to USD 1.414 billion (redefined from USD 1.400 billion to USD 1.413 billion in March).[2, 23] Management reaffirmed its full-year non-GAAP diluted EPS guidance of USD 4.58 to USD 4.66 and reaffirmed its long-term objective of generating more than USD 2.2 billion in aggregate free cash flow from fiscal year 2026 through fiscal year 2028.[2]
In the latest earnings materials, President and CEO Al White highlighted that the G&A restructuring completed in late fiscal year 2025—which incurred USD 89 million in cash and non-cash charges—is delivering on its expectations, yielding annual pre-tax savings of USD 50 million (or USD 0.19 per share) beginning in fiscal year 2026.[22, 24] These savings are being driven by the "OneCooper" initiative, which consolidated back-office operations into global support platforms using advanced information technology and artificial intelligence.[24] Management noted that these operational efficiencies helped offset tariff headwinds of USD 24 million, supporting a non-GAAP gross margin of 68% and expanding the non-GAAP operating margin by 260 basis points year-over-year to 27%.[2, 8, 9]
GAAP interest expense for the quarter declined to USD 20.9 million, compared with USD 24.2 million in the second quarter of fiscal year 2025, driven by debt paydown and lower interest rates.[2] Free cash flow for the second quarter reached USD 96.4 million, derived from cash provided by operations of USD 182.8 million offset by capital expenditures of USD 86.4 million.[2]
Cooper Companies trades at a trailing price-to-earnings (P/E) ratio of 30.65x and a forward P/E of approximately 12.4x based on expected non-GAAP earnings.[25, 26] This low forward multiple indicates that the market has discounted the stock due to near-term execution and litigation risks, presenting an attractive entry valuation relative to its historical premium. Prior to the earnings report, on June 1, 2026, Piper Sandler lowered its 12-month price target to USD 86 from USD 94 while maintaining an Overweight rating, citing FQ2 setup concerns.[27] Following the latest earnings report, Wall Street analysts adjusted their targets: Goldman Sachs maintained its Sell rating and lowered its target to USD 61 from USD 69, Citigroup maintained a Neutral rating while trimming its target to USD 69 from USD 80, and BNP Paribas trimmed its Outperform price target to USD 95 from USD 96.[28]
The primary operational risk relates to the integration and consolidation of the company’s G&A infrastructure under the "OneCooper" platform.[24] While the consolidation of back-office support functions is projected to generate USD 50 million in annual pre-tax savings, any failure in system migration, enterprise software implementation, or automated customer support could disrupt ordering channels, delay shipments to eye clinics, and damage critical relationships with practitioners.[5, 24]
In the contact lens market, Cooper face aggressive product rollouts and high marketing spend from Alcon and Johnson & Johnson, which could slow Cooper's silicone hydrogel conversion.[5] In the contraceptive space, Organon's commercial launch of Miudella, which features a smaller insertion profile and fewer side effects, presents a long-term competitive threat to CooperSurgical’s high-margin PARAGARD revenue.[12]
Revenue growth is sensitive to regional market dynamics, particularly in the Asia-Pacific region. Persistent demand softness for legacy hydrogel lenses in Japan, combined with weak e-commerce volumes in China, has historically dragged down international performance.[6, 8, 22] Failure to transition these legacy consumers to premium daily disposables would impair long-term top-line growth.[5, 22]
Regulatory and product liability risks represent a major concern for the company. Although CooperSurgical resolved the claims associated with the December 2023 fertility media recall for USD 271.6 million, the company remains a primary defendant in the PARAGARD multidistrict litigation, which contains over 3,749 active cases alleging device breakage and migration.[2, 9, 29] The second bellwether test trial is scheduled for Fall 2026, and any adverse rulings or large settlement outcomes could lead to material cash outflows and reputational damage among healthcare providers.[29]
The company holds a significant debt burden, with approximately USD 2.5 billion in total debt outstanding as of Q2 2026.[30] High leverage combined with high capital expenditure commitments for manufacturing capacity buildouts could restrict capital allocation flexibility, limit execution under the USD 2.0 billion share buyback authorization, or lead to credit rating downgrades.[24, 28]
Cooper is sensitive to international trade policies, with import tariffs on manufacturing inputs creating an estimated USD 24 million annual headwind.[8] The company is also exposed to foreign currency fluctuations, particularly the Euro and Japanese Yen, which can impact reported revenue and gross margins.[2, 6] Finally, sustained inflation in raw materials, medical packaging, and labor could compress operating margins if the company is unable to pass these costs on to customers.[13]
To evaluate the long-term total return potential for Cooper Companies, this model projects financials over a five-year period from the fiscal year 2026 base to fiscal year 2031.
The baseline calculations utilize the projected fiscal year 2026 revenue midpoint ($R_0$) of USD 4.303 billion, representing the updated guidance range of USD 4.285 billion to USD 4.321 billion [2], and the expected non-GAAP diluted earnings per share ($E_0$) of USD 4.62, representing the midpoint of guidance.[2] The baseline share count ($S_0$) is 195.11 million outstanding shares, and the current stock price ($P_0$) is USD 67.33, recorded on June 4, 2026.[20, 26]
Let $R_5$ be the Year 5 Revenue, $E_5$ be the Year 5 non-GAAP EPS, $g_R$ be the compound annual revenue growth rate, and $g_E$ be the compound annual EPS growth rate:
$R_5 = R_0 \times (1 + g_R)^5$
$E_5 = E_0 \times (1 + g_E)^5$
The Implied Future Share Price ($P_5$) is determined by applying the exit forward price-to-earnings multiple ($M_{exit}$) to the projected Year 5 EPS:
$P_5 = E_5 \times M_{exit}$
The Base Case assumes that CooperVision continues to gain market share through the expansion of its MyDay and clariti daily silicone hydrogel portfolios.[3, 5] CooperSurgical successfully navigates the PARAGARD litigation with moderate, manageable settlements, and competitive pressure from Organon’s Miudella is limited by its 3-year approval restriction.[12, 29]
The High Case assumes that CooperVision accelerates its premium silicone hydrogel conversions globally and expands pediatric myopia control penetration.[3, 5] CooperSurgical resolves the PARAGARD litigation with minimal liability, and fertility segment growth speeds up.[3, 29]
The Low Case assumes that CooperSurgical’s PARAGARD market share is eroded by Organon’s Miudella, and the PARAGARD litigation leads to substantial cash outflows.[12, 29] CooperVision faces pricing pressure from private-label contact lenses and sustained softness in the APAC region.[5, 8]
The probability-weighted share price target is calculated as:
$\text{Target Price} = (0.55 \times \$99.60) + (0.25 \times \$149.76) + (0.20 \times \$50.60)$
$\text{Target Price} = \$54.78 + \$37.44 + \$10.12 = \$102.34$
This weighted price target of USD 102.34 implies a potential total return of 52.00% (8.73% annualized) over the 5-year investment horizon relative to the current share price of USD 67.33.[20]
| Scenario | Revenue in Year 5 (Billions USD) | Margin / Earnings Assumption (Year 5 EPS) | Valuation Multiple Assumption (Forward P/E) | Current Share Price (USD) | Implied Future Share Price (USD) | 5-Year Total Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| Base Case | USD 5.758 | USD 6.79 | 15.0x | USD 67.33 | USD 99.60 | 47.93% | 8.14% | 55% |
| High Case | USD 6.470 | USD 8.32 | 18.0x | USD 67.33 | USD 149.76 | 122.43% | 17.34% | 25% |
| Low Case | USD 4.988 | USD 4.60 | 11.0x | USD 67.33 | USD 50.60 | -24.85% | -5.55% | 20% |
| Weighted Target | — | — | — | USD 67.33 | USD 102.34 | 52.00% | 8.73% | 100% |
ASYMMETRIC RETURN PROFILE
The qualitative performance of Cooper Companies has been evaluated across ten key corporate criteria. Each metric is scored on a scale of 1–10, followed by a narrative analysis that details the underlying factors.
| Metric | Score (1-10) | Key Qualitative Factors |
|---|---|---|
| Management Alignment | 8/10 | Large share buybacks; independent board expansions.[1, 24] |
| Revenue Quality | 8/10 | Subscription-like daily consumables, offset by recall liabilities.[2, 3] |
| Market Position | 9/10 | 18 consecutive years of global share gains in soft lenses.[3] |
| Growth Outlook | 7/10 | Strong daily silicone hydrogel demand; legacy hydrogel headwinds.[5, 8] |
| Financial Health | 7/10 | Strong free cash flow target, offset by USD 2.5B total debt.[2, 30] |
| Business Viability | 8/10 | High durability in eye and fertility care; emerging competitive threats.[5, 12] |
| Capital Allocation | 8/10 | Disciplined capital expenditures, balanced with opportunistic buybacks.[5, 24] |
| Analyst Sentiment | 7/10 | Wide divergence in price targets, reflecting near-term execution risk.[26, 28] |
| Profitability | 8/10 | Non-GAAP operating margin expanded to 27%; GAAP volatility.[2, 9] |
| Track Record | 8/10 | Durability in long-term sales expansion and market execution.[3, 13] |
| Overall Blended Score | 7.8 / 10 | Strong medical device operator with durable competitive positioning. |
ROBUST QUALITY PROFILE
Cooper Companies’ core ophthalmic and surgical businesses exhibit highly durable competitive positioning.[5] The contact lens division, CooperVision, is a consistent share gainer, successfully converting patients to high-margin daily disposable silicone hydrogel lenses and expanding its presence in pediatric myopia control.[3, 5] While CooperSurgical faces competitive pressure from Organon’s Miudella and ongoing litigation relating to the PARAGARD multidistrict lawsuit, the resolution of its fertility media recall claims eliminates a major legal overhang.[2, 9, 12, 29]
The G&A reorganization completed under the OneCooper initiative has successfully improved the company's cost structure, expanding the non-GAAP operating margin to 27%.[9, 24] Trading near USD 67.33, the stock trades at approximately 12.4x forward non-GAAP earnings.[25, 26] This valuation appears low relative to the company's long-term target of generating more than USD 2.2 billion in aggregate free cash flow through fiscal year 2028, presenting a potentially attractive entry valuation.[2] This analysis indicates that the probability-weighted target of USD 102.34 offers a favorable risk-reward profile, with an estimated 52.00% total return (8.73% annualized) over the 5-year investment horizon.
COMPASS FOR INVESTORS
Cooper Companies’ stock closed at USD 67.33 on June 4, 2026, gaining 8.56% following the release of its fiscal second-quarter 2026 financial results.[20] The stock is currently trading below its 200-day moving average, which stands between USD 72.93 and USD 74.27, suggesting a bearish intermediate-term trend that is beginning to show signs of a potential reversal.[20, 32] With its Relative Strength Index rising from an oversold level of 26.63 pre-earnings, the short-term outlook is positive as the stock attempts to build support around its recent lows.[33]
RECOVERY TRENDING UPWARD
View The Cooper Companies, Inc. (COO) stock page
Loading the interactive version of this report…